Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07433621
PHASE1

Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency

Sponsor: Children's Hospital Medical Center, Cincinnati

View on ClinicalTrials.gov

Summary

The purpose of the study is to evaluate safety and tolerability of oral quercetin in reducing inflammation in male patients with XIAP deficiency. Quercetin is a naturally occurring antioxidant that has many properties including the ability to decrease inflammation in other diseases.

Official title: A Pilot Study to Evaluate Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency

Key Details

Gender

MALE

Age Range

2 Years - Any

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2026-02-26

Completion Date

2029-06

Last Updated

2026-03-27

Healthy Volunteers

No

Conditions

Interventions

DRUG

Quercetin

Quercetin will be administered orally at a weight adjusted dose for a maximum total daily dose of 4000mg/day, divided twice a day. If the patient is 70 kg or more, the dose will automatically be assigned at the maximum dose of 4000mg/day. Patients will be instructed to mix quercetin with a small amount of yogurt or other preferred food for ingestion.

Locations (1)

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States